AnaptysBio Inc (ANAB) USD0.001

Sell:$20.64Buy:$20.70$0.09 (0.44%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$20.64
Buy:$20.70
Change:$0.09 (0.44%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$20.64
Buy:$20.70
Change:$0.09 (0.44%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.

Key people

John A. Orwin
Chairman of the Board
Daniel R. Faga
President, Chief Executive Officer, Director
Dennis M. Mulroy
Chief Financial Officer
Paul F. Lizzul
Chief Medical Officer
Eric Joseph Loumeau
Chief Legal Officer
Dennis Fenton
Independent Director
Rita Jain
Independent Director
Magda Marquet
Independent Director
Oleg Nodelman
Independent Director
Hollings C. Renton
Independent Director
Click to see more

Key facts

  • EPIC
    ANAB
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US0327241065
  • Market cap
    $626.22m
  • Employees
    136
  • Shares in issue
    30.67m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.